We found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleEtanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.AuthorsWang, F; Smith, N; Maier, L; Xia, W; Hammerberg, C; Chubb, H; Chen, C; Riblett, M; Johnston, A; Gudjonsson, J E; Helfrich, Y; Kang, S; Fisher, G J; Voorhees, J JAbstractPsoriasis is a Th17/Th1-mediated skin disease that often responds to antitumour necrosis factor (TNF)-α therapies, such as etanercept.PublicationThe British journal of dermatology, 2012, Vol 167, Issue 1, p92ISSN1365-2133Publication typeJournal ArticleDOI10.1111/j.1365-2133.2012.10961.x